| DrugRepV_0001 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Zika virus | Brazilian strain ZKV2015 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 29150641 |
| DrugRepV_0068 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_0069 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_0070 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_0093 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0094 | BMS-777607 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0095 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0096 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0097 | Ki8751 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0098 | Rebastinib | Anticancer | Chronic Myeloid Leukemia | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0099 | OSU-03012 | Anticancer | Brain cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0100 | GSK2656157 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | NA | 28099856 |
| DrugRepV_0101 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0102 | Flubendazole | Antiparasitic products, Insectisides and Repellents | Helminthiasis | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Experimental, Withdrawn | 28099856 |
| DrugRepV_0103 | Oxibendazole | Antiparasitic | Helminth intestinal infections | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational, Vet approved | 28099856 |
| DrugRepV_0104 | Albendazole | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Approved | 28099856 |
| DrugRepV_0105 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0106 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0107 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0108 | Cabazitaxel | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Approved | 28099856 |
| DrugRepV_0109 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0110 | RGFP966 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0111 | Dioscin | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0112 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0113 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0114 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0115 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0116 | Methotrexate | NA | Gestational choriocarcinoma | Chorioadenoma destruens | Hydatidiform mole | Meningeal leukemia | Breast cancer | Epidermoid cancers of the head and neck | Lung cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0117 | PF-04691502 | NA | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Investigational | 28099856 |
| DrugRepV_0118 | GDC-0980 | Anticancer | Solid Cancer | Breast Cancer | Prostate Cancer | Renal Cell Carcinoma | Endometrial Carcinoma | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Investigational | 28099856 |
| DrugRepV_0119 | Albendazole | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0120 | Navitoclax | NA | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0121 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Approved | 28099856 |
| DrugRepV_0122 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 28099856 |
| DrugRepV_0123 | GZD824 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (No significant effect No significant effect) | NA | 28099856 |
| DrugRepV_0124 | VE-822 | NA | Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (No significant effect No significant effect) | Investigational | 28099856 |
| DrugRepV_0125 | Amuvatinib | NA | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (No significant effect No significant effect) | Investigational | 28099856 |
| DrugRepV_0126 | NVP-BHG712 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (No significant effect No significant effect) | NA | 28099856 |
| DrugRepV_0127 | WAY-600 | NA | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0128 | YM201636 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | NA | 28099856 |
| DrugRepV_0129 | RGFP966 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0130 | QNZ | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0131 | Obatoclax Mesylate | Anticancer | Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Investigational | 28099856 |
| DrugRepV_0132 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0133 | STF-118804 | NA | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0134 | Cetylpyridinium Chloride | Blood and Blood Forming Organs; Antiseptics And Disinfectants; Dermatologicals; Respiratory System | Bacterial infections | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0135 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0136 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0137 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (80 %) | NA | 28099856 |
| DrugRepV_0138 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (80 %) | Approved | 28099856 |
| DrugRepV_0139 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (90 %) | Approved | 28099856 |
| DrugRepV_0140 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0141 | Tenovin-1 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (80 %) | NA | 28099856 |
| DrugRepV_0142 | Tenovin-1 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | NA | 28099856 |
| DrugRepV_0143 | Tenovin-1 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | NA | 28099856 |
| DrugRepV_0144 | AMG-458 | NA | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (60 %) | NA | 28099856 |
| DrugRepV_0145 | AMG-458 | NA | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | NA | 28099856 |
| DrugRepV_0146 | AMG-458 | NA | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (10 %) | NA | 28099856 |
| DrugRepV_0147 | MGCD-265 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (60 %) | Investigational | 28099856 |
| DrugRepV_0148 | MGCD-265 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (25 %) | Investigational | 28099856 |
| DrugRepV_0149 | MGCD-265 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Investigational | 28099856 |
| DrugRepV_0150 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_0151 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Approved | 28099856 |
| DrugRepV_0152 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Approved | 28099856 |
| DrugRepV_0153 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_0154 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Investigational | 28099856 |
| DrugRepV_0155 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Increase (120 %) | Investigational | 28099856 |
| DrugRepV_0156 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0157 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (80 %) | NA | 28099856 |
| DrugRepV_0158 | Nanchangmycin | Antibacterial; Antiviral | NA | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (90 %) | NA | 28099856 |
| DrugRepV_0159 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0160 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (90 %) | Approved | 28099856 |
| DrugRepV_0161 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0162 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0163 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0164 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (40 %) | NA | 28099856 |
| DrugRepV_0165 | AMG-458 | NA | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (60 %) | NA | 28099856 |
| DrugRepV_0166 | AMG-458 | NA | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | NA | 28099856 |
| DrugRepV_0167 | AMG-458 | NA | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (30 %) | NA | 28099856 |
| DrugRepV_0168 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_0169 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_0170 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (40 %) | Investigational | 28099856 |
| DrugRepV_0171 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0172 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_0173 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (40 %) | Approved | 28099856 |
| DrugRepV_0174 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (60 %) | Investigational | 28099856 |
| DrugRepV_0175 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (60 %) | Investigational | 28099856 |
| DrugRepV_0176 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (0 %) | Investigational | 28099856 |
| DrugRepV_0198 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0199 | Chloroquine | Antiparasitic products, Insectisides and Repellents | malaria | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27890675 |
| DrugRepV_0200 | Maprotiline | Nervous System | Bipolar depression | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0201 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0202 | Azithromycin | Antiinfectives For Systemic Use | Microbial infections | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27890675 |
| DrugRepV_0203 | Clarithromycin | Antiinfectives For Systemic Use | Microbial infections | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27890675 |
| DrugRepV_0204 | Posaconazole | Antiinfectives For Systemic Use | Fungal infections (Aspergillus and Candida infections) | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational, Vet approved | 27890675 |
| DrugRepV_0205 | Toremifene-Clarithromycin-Posaconazole | NA | NA | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27890675 |
| DrugRepV_0206 | Toremifene-Mefloquine-Posaconazole | NA | NA | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27890675 |
| DrugRepV_0207 | Chloroquine-Maprotiline-Azithromycin | NA | Malaria and Depression | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27890675 |
| DrugRepV_0208 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0209 | Posaconazole | Antiinfectives For Systemic Use | Fungal infections (Aspergillus and Candida infections) | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational, Vet approved | 27890675 |
| DrugRepV_0210 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0211 | Clarithromycin | Antiinfectives For Systemic Use | Microbial infections | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27890675 |
| DrugRepV_0212 | Maprotiline | Nervous System | Bipolar depression | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0213 | Toremifene-Clarithromycin-Posaconazole | NA | NA | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (>90 %) | NA | 27890675 |
| DrugRepV_0214 | Toremifene-Mefloquine-Posaconazole | NA | NA | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (74 %) | NA | 27890675 |
| DrugRepV_0296 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Anhui/1/ 2013 |  | Immunoflourescence assay | Decrease (50 %) | Investigational | 26192013 |
| DrugRepV_0297 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/California/04/09 | | Immunoflourescence assay | Decrease (50 %) | Investigational | 26192013 |
| DrugRepV_0298 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Philippines/2/82-X79 | | Immunoflourescence assay | Decrease (50 %) | Investigational | 26192013 |
| DrugRepV_0299 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Anhui/1/ 2013 | | Immunoflourescence assay | Decrease (50 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0300 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/California/04/09 | | Immunoflourescence assay | Decrease (50 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0301 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Philippines/2/82-X79 | | Immunoflourescence assay | Decrease (50 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0302 | PIK-75 | NA | NA | Influenza virus | A/Anhui/1/ 2013 | | Immunoflourescence assay | Decrease (50 %) | NA | 26192013 |
| DrugRepV_0303 | PIK-75 | NA | NA | Influenza virus | A/California/04/09 | | Immunoflourescence assay | Decrease (50 %) | NA | 26192013 |
| DrugRepV_0304 | PIK-75 | NA | NA | Influenza virus | A/Philippines/2/82-X79 | | Immunoflourescence assay | Decrease (50 %) | NA | 26192013 |
| DrugRepV_0311 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Mississippi/3/01 wt | | Immunoflourescence assay | Decrease (>95 %) | Investigational | 26192013 |
| DrugRepV_0312 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Mississippi/3/01 H275Y | | Immunoflourescence assay | Decrease (95 %) | Investigational | 26192013 |
| DrugRepV_0313 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Mississippi/3/01 wt | | Immunoflourescence assay | Decrease (>95 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0314 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Mississippi/3/01 H275Y | | Immunoflourescence assay | Decrease (90 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0315 | PIK-75 | NA | NA | Influenza virus | A/Mississippi/3/01 wt | | Immunoflourescence assay | Decrease (90 %) | NA | 26192013 |
| DrugRepV_0316 | PIK-75 | NA | NA | Influenza virus | A/Mississippi/3/01 H275Y | | Immunoflourescence assay | Decrease (85 %) | NA | 26192013 |
| DrugRepV_0317 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational, Vet approved | 27622822 |
| DrugRepV_0318 | Mebendazole | Antiparasitic products, Insectisides and Repellents | Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections) | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Vet approved | 27622822 |
| DrugRepV_0319 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0320 | Procainamide | Cardiovascular agents | Ventricular arrhythmias | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0321 | Azithromycin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0322 | Chlortetracycline | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0323 | Clemastine | Respiratory System | Sneezing, rhinorrhea, pruritus and acrimation | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0324 | Benztropine | Nervous System | Parkinson disease | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0325 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0326 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0327 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0328 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0329 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0330 | Thiothixene | Nervous System | Schizophrenia | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0331 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Vet approved | 27622822 |
| DrugRepV_0332 | Fluphenazine | Nervous System | Psychosis | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0333 | Perphenazine | Nervous System | Psychosis | Nausea and vomiting in adults | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0334 | Promazine | Nervous System | Psychomotor agitation | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Vet approved | 27622822 |
| DrugRepV_0335 | Paroxetine | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27622822 |
| DrugRepV_0336 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0337 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0713 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | Musoke | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0714 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | Musoke | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0715 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | Musoke | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0716 | Aminoquinoline-13 | NA | Malaria | Marburg virus | Musoke | NA | Immunoflourescence assay | Decrease (50 %) | NA | 23577127 |
| DrugRepV_1936 | Manidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_1937 | Cilnidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_1938 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease | Approved | 28814523 |
| DrugRepV_1939 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease | Approved, Investigational | 28814523 |
| DrugRepV_1940 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease | Approved | 28814523 |
| DrugRepV_1942 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Zika virus | SZ-WIV01 | NA | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational, Vet approved | 28480282 |
| DrugRepV_1953 | Tizoxanide | Antiparasitic products, Insectisides and Repellents | Crytosporidiosis and Giardiasis | Zika virus | SZ-WIV01 | NA | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational, Vet approved | 28480282 |
| DrugRepV_2056 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Chikungunya virus | S27 | NA | Immunoflourescence assay | Decrease | Approved | 27742486 |
| DrugRepV_2057 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Chikungunya virus | S27 | NA | Immunoflourescence assay | Decrease | Approved, Investigational, Vet approved | 27742486 |
| DrugRepV_2067 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Severe acute respiratory syndrome coronavirus | NA | NA | Immunoflourescence assay | Decrease | Approved | 15215127 |
| DrugRepV_2137 | 7-deaza-2-C-methyl-D-adenosine | NA | Viral infection | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27163257 |
| DrugRepV_2951 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Chikungunya virus | DRDE-06 | NA | Immunoflourescence assay | Decrease | Approved | 20336760 |
| DrugRepV_3088 | Nigericin Sodium | Antibiotics | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (100 %) | NA | 23275491 |
| DrugRepV_3089 | Dipterocarpol | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (100 %) | NA | 23275491 |
| DrugRepV_3090 | Anisomycin | Antibacterial | Bacterial infection | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.96 %) | Experimental | 23275491 |
| DrugRepV_3091 | Aloe-emodin | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.89 %) | NA | 23275491 |
| DrugRepV_3092 | Retrorsine | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.84 %) | NA | 23275491 |
| DrugRepV_3093 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.82 %) | Approved | 23275491 |
| DrugRepV_3094 | Harringtonine | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.76 %) | NA | 23275491 |
| DrugRepV_3095 | Tetrahydrolipstatin | Alimentary Tract and Metabolism | Obesity | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.73 %) | Approved | 23275491 |
| DrugRepV_3096 | Tunicamycin B | NA | Bacterial infections | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.7 %) | Experimental | 23275491 |
| DrugRepV_3097 | Corydaline | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.69 %) | NA | 23275491 |
| DrugRepV_3098 | Ellagic Acid | Antioxidant and Anti-proliferative | Follicular Lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.61 %) | Investigational | 23275491 |
| DrugRepV_3099 | Lycorine Hydrochloride | Antiviral, Antimalarial, Anticancer and Antiinflammatory | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.59 %) | NA | 23275491 |
| DrugRepV_3100 | Usnic Acid | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.54 %) | NA | 23275491 |
| DrugRepV_3101 | Rhapontin | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.53 %) | NA | 23275491 |
| DrugRepV_3102 | Emetine Dihydrochloride | Antiparasitic products, Insectisides and Repellents | Protozoal disease | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.5 %) | NA | 23275491 |
| DrugRepV_3103 | Ferutinin | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.43 %) | NA | 23275491 |
| DrugRepV_3104 | Diacetoxyscirpenol | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.27 %) | NA | 23275491 |
| DrugRepV_3105 | Bleomycin | Antineoplastic and Immunomodulating Agents | Bacterial infection and cancer | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.27 %) | Approved | 23275491 |
| DrugRepV_3106 | Cycloheximide | Antibacterial | Bacterial infections | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.1 %) | NA | 23275491 |
| DrugRepV_3107 | Acivicin | NA | Cancer | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.07 %) | Phase I | 23275491 |
| DrugRepV_3108 | Narasin | Antibacterial | Parasitic and bacterial infections | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (98.89 %) | Experimental | 23275491 |
| DrugRepV_3109 | Jervine | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (98.35 %) | NA | 23275491 |
| DrugRepV_3110 | Hypocrellin B | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (98.08 %) | NA | 23275491 |
| DrugRepV_3111 | Valinomycin | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (97.79 %) | Experimental | 23275491 |
| DrugRepV_3112 | Hypocrellin A | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (97.64 %) | NA | 23275491 |
| DrugRepV_3113 | Menadione | Blood and Blood Forming Organs | Blood clotting | Bone calcification | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (97.53 %) | Approved, Nutraceutical | 23275491 |
| DrugRepV_3114 | E-64 | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (95.94 %) | NA | 23275491 |
| DrugRepV_3115 | Magnolol | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (95.74 %) | NA | 23275491 |
| DrugRepV_3116 | Daunorubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Leukemia | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (95.56 %) | Approved | 23275491 |
| DrugRepV_3117 | Nonactin | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (95.31 %) | NA | 23275491 |
| DrugRepV_3118 | Antimycin A1 | Antifungal | Fungal infections | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (94.99 %) | NA | 23275491 |
| DrugRepV_3119 | Ochratoxin A | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (94.95 %) | NA | 23275491 |
| DrugRepV_3120 | Papaverine hydrochloride | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (94.76 %) | Approved, Investigational | 23275491 |
| DrugRepV_3121 | Parthenolide | NA | Allergic Contact Dermatitis | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (93.95 %) | Approved, Investigational | 23275491 |
| DrugRepV_3122 | Vinblastine Sulfate | Antineoplastic and Immunomodulating Agents | Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma) | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (93.75 %) | Approved | 23275491 |
| DrugRepV_3123 | Chelidonine | Plant extract | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (93.22 %) | NA | 23275491 |
| DrugRepV_3124 | Rottlerin | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (92.81 %) | NA | 23275491 |
| DrugRepV_3125 | Grayanotoxin III | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (91.39 %) | NA | 23275491 |
| DrugRepV_3126 | Gossypol | NA | Non-small Cell Lung Cancer | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (90.89 %) | Investigational | 23275491 |
| DrugRepV_3127 | Sanguinarine | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (90.83 %) | NA | 23275491 |
| DrugRepV_3128 | Mithramycin A | Antineoplastic and Immunomodulating Agents | Testicular cancer | Hypercalcemia | Hypercalciuria | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (87.96 %) | Approved | 23275491 |
| DrugRepV_3129 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (86.92 %) | Approved | 23275491 |
| DrugRepV_3130 | Cyclopiazonic Acid | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (79.93 %) | NA | 23275491 |
| DrugRepV_3131 | Harmine Hydrochloride | NA | NA | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (73.68 %) | NA | 23275491 |
| DrugRepV_3470 | Pyrrolopyridinamine PPA-7 | NA | NA | Influenza virus | CA/09 (H1N1) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3471 | Aminothiadiazole ATD-1 | NA | NA | Influenza virus | CA/09 (H1N1) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3472 | Dihydrofuropyridine carboxamide HPC-2 | NA | NA | Influenza virus | CA/09 (H1N1) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3473 | Pyrrolopyridinamine PPA-7 | NA | NA | Influenza virus | PE/09 (H3N2) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3474 | Aminothiadiazole ATD-1 | NA | NA | Influenza virus | PE/09 (H3N2) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3475 | Dihydrofuropyridine carboxamide HPC-2 | NA | NA | Influenza virus | PE/09 (H3N2) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3476 | Pyrrolopyridinamine PPA-7 | NA | NA | Influenza virus | B/Florida/04/2006 (B/FL/06) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3477 | Aminothiadiazole ATD-1 | NA | NA | Influenza virus | B/Florida/04/2006 (B/FL/06) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3478 | Dihydrofuropyridine carboxamide HPC-2 | NA | NA | Influenza virus | B/Florida/04/2006 (B/FL/06) | | Immunoflourescence assay | Decrease (50 %) | NA | 27586275 |
| DrugRepV_3733 | OSU-03012 | Anticancer | Brain cancer | Lassa virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_4220 | Arbidol | NA | NA | Chikungunya virus | LR2006 OPY1 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 21440006 |
| DrugRepV_4221 | HZ2a | NA | NA | Chikungunya virus | LR2006 OPY1 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 21440006 |
| DrugRepV_4222 | 6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phe- nylsulphonylmethyl)-1H-indole-3-carboxylate | NA | NA | Chikungunya virus | LR2006 OPY1 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 21440006 |
| DrugRepV_4223 | 6-bromo- 4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(methylphenyl- sulphoxyde)-1H-indole-3-carboxylate | NA | NA | Chikungunya virus | LR2006 OPY1 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 21440006 |
| DrugRepV_4296 | Piperazine | Antiparasitic products, Insectisides and Repellents | Parasitic infections (Ascariasis) | Chikungunya virus | DRDE-07 | NA | Immunoflourescence assay | Decrease | Approved, Vet approved | 28842264 |
| DrugRepV_4480 | Brincidofovir | Antiviral | Viral infections | Ebola virus | Ebola Zaire Kikwit | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 26526586 |
| DrugRepV_4481 | Brincidofovir | Antiviral | Viral infections | Ebola virus | Ebola Zaire Kikwit | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 26526586 |
| DrugRepV_4482 | Brincidofovir | Antiviral | Viral infections | Ebola virus | Ebola Zaire Kikwit | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 26526586 |
| DrugRepV_4483 | Brincidofovir | Antiviral | Viral infections | Ebola virus | Ebola Zaire Makona | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 26526586 |
| DrugRepV_4484 | Brincidofovir | Antiviral | Viral infections | Ebola virus | Ebola Zaire Makona | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 26526586 |
| DrugRepV_4485 | Brincidofovir | Antiviral | Viral infections | Ebola virus | Ebola Zaire Makona | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 26526586 |
| DrugRepV_4653 | Palonosetron | Alimentary Tract and Metabolism | Nausea and vomiting associated with cancer chemotherapy | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27909576 |
| DrugRepV_4654 | 6-Azauridine | NA | Cancer | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4655 | 5-Fluorouracil | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27909576 |
| DrugRepV_4656 | Lovastatin | Cardiovascular agents | Atherosclerotic vascular disease | Hypercholesterolemia | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27909576 |
| DrugRepV_4657 | Kitasamycin | NA | Bacterial infections | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Experimental | 27909576 |
| DrugRepV_4658 | SAM002589981 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4659 | SAM002564206 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4660 | SAM002564189 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4661 | SAM002554886 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4662 | SAM002548975 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4663 | SAM002548938 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4664 | SAM002264636 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4665 | SAM001247107 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4666 | SAM001247103 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4667 | SAM001247083 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4668 | SAM001247075 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4669 | SAM001247056 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4670 | SAM001247054 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4671 | SAM001247052 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4672 | SAM001247038 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4673 | SAM001246989 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4674 | SAM001246979 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4675 | SAM001246977 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4676 | SAM001246883 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4677 | SAM001246690 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4678 | SAM001246644 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4679 | SAM001246622 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4680 | SAM001246545 | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 27909576 |
| DrugRepV_4709 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Zika virus | NA | NA | Immunoflourescence assay | Decrease | Approved | 30061280 |
| DrugRepV_4710 | 2,4-dichloro-6-(3,4-dibromo-5-fluoro-1H-pyrrole-2-carbonyl)phenol | NA | NA | Zika virus | NA | NA | Immunoflourescence assay | Decrease | NA | 30061280 |
| DrugRepV_4726 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | Decrease | Approved | 29566060 |
| DrugRepV_4727 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | No significant effect | Approved | 29566060 |
| DrugRepV_4728 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 29566060 |
| DrugRepV_5089 | S-Nitroso-N-acetylpenicillamine | NA | NA | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Immunoflourescence assay | Decrease (>90 %) | NA | 16632039 |
| DrugRepV_5180 | C795-0925 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5181 | D011-2120 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5182 | F694-1532 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5183 | G202-0362 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5184 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5185 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5186 | C795-0925 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5187 | D011-2120 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5188 | F694-1532 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5189 | G202-0362 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5190 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5191 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5192 | C795-0925 | NA | NA | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5193 | D011-2120 | NA | NA | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5194 | F694-1532 | NA | NA | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5195 | G202-0362 | NA | NA | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5196 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5197 | C795-0925 | NA | NA | Marburg virus | Ci67 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5198 | D011-2120 | NA | NA | Marburg virus | Ci67 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5199 | F694-1532 | NA | NA | Marburg virus | Ci67 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5200 | G202-0362 | NA | NA | Marburg virus | Ci67 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5201 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Marburg virus | Ci67 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5202 | C795-0925 | NA | NA | Lassa virus | Josiah | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5203 | D011-2120 | NA | NA | Lassa virus | Josiah | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5204 | F694-1532 | NA | NA | Lassa virus | Josiah | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5205 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Lassa virus | Josiah | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5606 | Nanchangmycin | Antibacterial; Antiviral | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_5607 | Nanchangmycin | Antibacterial; Antiviral | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_5608 | Nanchangmycin | Antibacterial; Antiviral | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (80 %) | NA | 28099856 |
| DrugRepV_5609 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_5610 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (90 %) | Approved | 28099856 |
| DrugRepV_5611 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (80 %) | Approved | 28099856 |
| DrugRepV_5612 | Tenovin-1 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (90 %) | NA | 28099856 |
| DrugRepV_5613 | Tenovin-1 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_5614 | Tenovin-1 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (10 %) | NA | 28099856 |
| DrugRepV_5615 | AMG-458 | NA | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (60 %) | NA | 28099856 |
| DrugRepV_5616 | AMG-458 | NA | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (40 %) | NA | 28099856 |
| DrugRepV_5617 | AMG-458 | NA | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (5 %) | NA | 28099856 |
| DrugRepV_5618 | MGCD-265 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_5619 | MGCD-265 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (25 %) | Investigational | 28099856 |
| DrugRepV_5620 | MGCD-265 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (20 %) | Investigational | 28099856 |
| DrugRepV_5621 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (60 %) | Approved | 28099856 |
| DrugRepV_5622 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (30 %) | Approved | 28099856 |
| DrugRepV_5623 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (10 %) | Approved | 28099856 |
| DrugRepV_5624 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (80 %) | Investigational | 28099856 |
| DrugRepV_5625 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (25 %) | Investigational | 28099856 |
| DrugRepV_5626 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Increase (120 %) | Investigational | 28099856 |
| DrugRepV_5803 | Lapachaone Alpha | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (98.84 %) | NA | 22155902 |
| DrugRepV_5804 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | NA | | Immunoflourescence assay | Decrease (92.38 %) | Approved | 22155902 |
| DrugRepV_5805 | Lycorine Hydrochloride | Antiviral, Antimalarial, Anticancer and Antiinflammatory | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (86.86 %) | NA | 22155902 |
| DrugRepV_5806 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Dengue virus | NA | | Immunoflourescence assay | Decrease (84.62 %) | Approved, Investigational, Vet approved | 22155902 |
| DrugRepV_5807 | C6 Ceramide | Dermatologicals | Skin disorder | Dengue virus | NA | | Immunoflourescence assay | Decrease (84.06 %) | Approved | 22155902 |
| DrugRepV_5808 | Anisomycin | Antibacterial | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (82.49 %) | Experimental | 22155902 |
| DrugRepV_5809 | Shikonin | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (78.94 %) | NA | 22155902 |
| DrugRepV_5810 | Cycloheximide | Antibacterial | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (78.71 %) | NA | 22155902 |
| DrugRepV_5811 | Chelerythrine Chloride | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (73.36 %) | NA | 22155902 |
| DrugRepV_5812 | Skimmianine | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (61.96 %) | NA | 22155902 |
| DrugRepV_5813 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | NA | | Immunoflourescence assay | Decrease (59.6 %) | Approved | 22155902 |
| DrugRepV_5814 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (55.89 %) | Experimental | 22155902 |
| DrugRepV_5815 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Dengue virus | NA | | Immunoflourescence assay | Decrease (55.12 %) | Approved, Investigational | 22155902 |
| DrugRepV_5816 | Tunicamycin B | NA | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (55.01 %) | Experimental | 22155902 |
| DrugRepV_5817 | Acivicin | NA | Cancer | Dengue virus | NA | | Immunoflourescence assay | Decrease (54.32 %) | Phase I | 22155902 |
| DrugRepV_5818 | Cotinine | Nervous System | Psychosis | Dengue virus | NA | | Immunoflourescence assay | Decrease (52.71 %) | Withdrawn | 22155902 |
| DrugRepV_5819 | Cantharidin | Dermatologicals | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (51.87 %) | Approved | 22155902 |
| DrugRepV_5820 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Dengue virus | NA | | Immunoflourescence assay | Decrease (50.92 %) | Phase I | 22155902 |
| DrugRepV_5821 | Gitoxigenin | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (49.01 %) | NA | 22155902 |
| DrugRepV_5822 | Kainic Acid | NA | Neuroexcitatory | Dengue virus | NA | | Immunoflourescence assay | Decrease (48.87 %) | NA | 22155902 |
| DrugRepV_5823 | Brefeldin A | Antibiotics | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (47.12 %) | Experimental | 22155902 |
| DrugRepV_5824 | Dicoumarol | Blood and Blood Forming Organs | Coagulation disorders | Dengue virus | NA | | Immunoflourescence assay | Decrease (45.99 %) | Approved | 22155902 |
| DrugRepV_5825 | Diacetoxyscirpenol | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (45.55 %) | NA | 22155902 |
| DrugRepV_5826 | Austricin | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (45.01 %) | NA | 22155902 |
| DrugRepV_5827 | Valinomycin | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (43.34 %) | Experimental | 22155902 |
| DrugRepV_5828 | Thapsigargin | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (42.9 %) | NA | 22155902 |
| DrugRepV_5829 | Strophanthidin Acetate | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (41.96 %) | NA | 22155902 |
| DrugRepV_5830 | Trimethylpsoralen,4,5,8- | Dermatologicals | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (41.86 %) | NA | 22155902 |
| DrugRepV_5831 | Echinomycin | NA | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (41.52 %) | NA | 22155902 |
| DrugRepV_5832 | Chromomycin A3 | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (40.87 %) | NA | 22155902 |
| DrugRepV_5833 | Anisomycin | Antibacterial | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (50 %) | Experimental | 22155902 |
| DrugRepV_5834 | Lycorine Hydrochloride | Antiviral, Antimalarial, Anticancer and Antiinflammatory | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (50 %) | NA | 22155902 |
| DrugRepV_5835 | Strophanthidin Acetate | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (50 %) | NA | 22155902 |
| DrugRepV_5836 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (50 %) | Experimental | 22155902 |
| DrugRepV_5837 | Anisomycin | Antibacterial | Bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (100 %) | Experimental | 22155902 |
| DrugRepV_5838 | Lycorine Hydrochloride | Antiviral, Antimalarial, Anticancer and Antiinflammatory | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (98 %) | NA | 22155902 |
| DrugRepV_5839 | Strophanthidin Acetate | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (98 %) | NA | 22155902 |
| DrugRepV_5840 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (80 %) | Experimental | 22155902 |
| DrugRepV_5849 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | No significant effect (0 %) | Experimental | 22155902 |
| DrugRepV_5850 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease | Experimental | 22155902 |
| DrugRepV_5851 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease | Experimental | 22155902 |
| DrugRepV_5855 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | No significant effect (0 %) | Experimental | 22155902 |
| DrugRepV_5856 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | NA | | Immunoflourescence assay | Decrease (90 %) | Experimental | 22155902 |
| DrugRepV_5869 | N-Desmethylclozapine | Antipsychotic | Schizophrenia | Schizoaffective disorders | Dengue virus | NA | | Immunoflourescence assay | Decrease (0 %) | Investigational | 27572397 |
| DrugRepV_5870 | Fluoxetine | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Dengue virus | NA | | Immunoflourescence assay | Decrease (0 %) | Approved, Vet approved | 27572397 |
| DrugRepV_5871 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Immunoflourescence assay | Decrease (0 %) | Approved | 27572397 |
| DrugRepV_5929 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease | Approved | 25028694 |
| DrugRepV_5930 | Prochlorperazine Novamin | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50 %) | Approved | 25028694 |
| DrugRepV_5931 | Prochlorperazine Dimaleate | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50 %) | Approved | 25028694 |
| DrugRepV_5972 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Dengue virus | New Guinea | | Immunoflourescence assay | Decrease | Approved | 24773578 |
| DrugRepV_5994 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_5995 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_5996 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_5997 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_6166 | Thiosemicarbazide | NA | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease | NA | 27490721 |
| DrugRepV_6316 | Lapachaone Alpha | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (98.84 %) | NA | 22155902 |
| DrugRepV_6317 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (92.38 %) | Approved | 22155902 |
| DrugRepV_6318 | Lycorine Hydrochloride | Antiviral, Antimalarial, Anticancer and Antiinflammatory | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50 %) | NA | 22155902 |
| DrugRepV_6319 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (84.62 %) | Approved, Investigational, Vet approved | 22155902 |
| DrugRepV_6320 | C6 Ceramide | Dermatologicals | Skin disorder | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (84.06 %) | Approved | 22155902 |
| DrugRepV_6321 | Anisomycin | Antibacterial | Bacterial infection | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (82.49 %) | Experimental | 22155902 |
| DrugRepV_6322 | Shikonin | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (78.94 %) | NA | 22155902 |
| DrugRepV_6323 | Cycloheximide | Antibacterial | Bacterial infections | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (78.71 %) | NA | 22155902 |
| DrugRepV_6324 | Chelerythrine Chloride | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (73.36 %) | NA | 22155902 |
| DrugRepV_6325 | Skimmianine | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (61.96 %) | NA | 22155902 |
| DrugRepV_6326 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (59.6 %) | Approved | 22155902 |
| DrugRepV_6327 | Narasin | Antibacterial | Parasitic and bacterial infections | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50 %) | Experimental | 22155902 |
| DrugRepV_6328 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (55.12 %) | Approved, Investigational | 22155902 |
| DrugRepV_6329 | Tunicamycin B | NA | Bacterial infections | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (55.01 %) | Experimental | 22155902 |
| DrugRepV_6330 | Acivicin | NA | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (54.32 %) | Phase I | 22155902 |
| DrugRepV_6331 | Cotinine | Nervous System | Psychosis | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (52.71 %) | Withdrawn | 22155902 |
| DrugRepV_6332 | Cantharidin | Dermatologicals | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (51.87 %) | Approved | 22155902 |
| DrugRepV_6333 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50.92 %) | Phase I | 22155902 |
| DrugRepV_6334 | Gitoxigenin | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (49.01 %) | NA | 22155902 |
| DrugRepV_6335 | Kainic acid | NA | Neuroexcitatory | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (48.87 %) | NA | 22155902 |
| DrugRepV_6336 | Brefeldin A | Antibiotics | Bacterial infections | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (47.12 %) | Experimental | 22155902 |
| DrugRepV_6337 | Dicoumarol | Blood and Blood Forming Organs | Coagulation disorders | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (45.99 %) | Approved | 22155902 |
| DrugRepV_6338 | Diacetoxyscirpenol | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (45.55 %) | NA | 22155902 |
| DrugRepV_6339 | Austricin | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (45.01 %) | NA | 22155902 |
| DrugRepV_6340 | Valinomycin | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (43.34 %) | Experimental | 22155902 |
| DrugRepV_6341 | Thapsigargin | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (42.9 %) | NA | 22155902 |
| DrugRepV_6342 | Strophanthidin acetate | Others | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50 %) | NA | 22155902 |
| DrugRepV_6343 | Trimethylpsoralen, 4,5,8- | Dermatologicals | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (41.86 %) | NA | 22155902 |
| DrugRepV_6344 | Echinomycin | NA | Bacterial infections | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (41.52 %) | NA | 22155902 |
| DrugRepV_6345 | Chromomycin A3 | NA | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (40.87 %) | NA | 22155902 |
| DrugRepV_7026 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_7027 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_7028 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_7029 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_7030 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | NA | 28814523 |
| DrugRepV_7046 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (45 %) | Approved | 28814523 |
| DrugRepV_7047 | 2-Aminobiphenyl borate | NA | NA | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (18 %) | NA | 28814523 |
| DrugRepV_7048 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (30 %) | Approved | 28814523 |
| DrugRepV_7049 | 1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic Acid | NA | NA | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (60 %) | NA | 28814523 |
| DrugRepV_7050 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (35 %) | Approved | 28814523 |
| DrugRepV_7051 | 2-Aminobiphenyl borate | NA | NA | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (20 %) | NA | 28814523 |
| DrugRepV_7052 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (45 %) | Approved | 28814523 |
| DrugRepV_7053 | 1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic Acid | NA | NA | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (45 %) | NA | 28814523 |
| DrugRepV_7108 | N-nonyl-deoxynojirimycin | NA | NA | Japanese encephalitis virus | RP-9 | | Immunoflourescence assay | Decrease (90 %) | NA | 11907199 |
| DrugRepV_7208 | CCG-4088 | NA | NA | Yellow fever virus | YFV 17D | | Immunoflourescence assay | Decrease | NA | 19651907 |
| DrugRepV_7209 | CCG-3394 | NA | NA | Yellow fever virus | YFV 17D | | Immunoflourescence assay | Decrease | NA | 19651907 |
| DrugRepV_7236 | 2-(3-chlorophenoxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Immunoflourescence assay | Decrease | NA | 28068627 |
| DrugRepV_7237 | 2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Immunoflourescence assay | Decrease | NA | 28068627 |
| DrugRepV_7324 | N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide | NA | NA | Japanese encephalitis virus | P3 | | Immunoflourescence assay | Decrease (86.71 %) | NA | 27679979 |
| DrugRepV_7325 | N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide | NA | NA | Japanese encephalitis virus | P3 | | Immunoflourescence assay | Decrease (89.3 %) | NA | 27679979 |
| DrugRepV_7338 | FGIN-1-27 | NA | NA | Japanese encephalitis virus | P3 | | Immunoflourescence assay | Decrease (80 %) | NA | 24348901 |
| DrugRepV_7339 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | P3 | | Immunoflourescence assay | Decrease (60 %) | Investigational | 24348901 |
| DrugRepV_7340 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Japanese encephalitis virus | P3 | | Immunoflourescence assay | Decrease (30 %) | Approved | 24348901 |